10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 6 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Fingolimod (FTY720) HCl Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.
In vitro
The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group.
In vivo
FTY720 is effective in Ph+ but not Ph- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph+ ALL xenografts using an early disease model. Ph+ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph- ALL xenografts.
Cell Data
cell lines：Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations：10 nM
Incubation Time：4 hours
Powder Purity:≥99%
| Isómeros SMILES | CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl |
|---|---|
| WGK Alemania | 3 |
| Peso molecular | 343.93 |
| Reaxy-Rn | 7837310 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=7837310&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Punto de fusión (°C) | 110 °C |
|---|
| 1. Ziqi Zhou, Yan Zhang, Simin Xia, Xi Chen. (2023) Red-Light-Activatable AND-Gated Antitumor Immunosuppressant. Cells, 12 (19): (2351). [PMID:37830565] [10.3390/cells12192351] |
| 2. Fan Yang, Dongju Zhao, Meng Cheng, Yining Liu, Ziyao Chen, Jin Chang, Yan Dou. (2023) mTOR-Mediated Immunometabolic Reprogramming Nanomodulators Enable Sensitive Switching of Energy Deprivation-Induced Microglial Polarization for Alzheimer’s Disease Management. ACS Nano, [PMID:37565731] [10.1021/acsnano.3c03232] |
| 3. Zhou Songlei, Huang Yukun, Chen Yu, Liu Yipu, Xie Laozhi, You Yang, Tong Shiqiang, Xu Jianpei, Jiang Gan, Song Qingxiang, Mei Ni, Ma Fenfen, Gao Xiaoling, Chen Hongzhuan, Chen Jun. (2023) Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. Nature Communications, 14 (1): (1-20). [PMID:36702831] [10.1038/s41467-023-35957-8] |
| 4. Yan-Jia Che, Xiao-He Ren, Zhi-Wei Wang, Qi Wu, Kai Xing, Min Zhang, Chang Xu, Di Han, Shun Yuan, Si-Hao Zheng, Yuan-Yang Chen, Xin-Ru Liao, Feng Shi, Xiao-Han Zhong, Xin Cai, Si-Xue Cheng. (2022) Lymph-Node-Targeted Drug Delivery for Effective Immunomodulation to Prolong the Long-Term Survival After Heart Transplantation. ADVANCED MATERIALS, 35 (16): (2207227). [PMID:36314402] [10.1002/adma.202207227] |
| 5. Taiying Chen, Ngalei Tam, Yu Mao, Chengjun Sun, Zekang Wang, Yuchen Hou, Wuzheng Xia, Jia Yu, Linwei Wu. (2022) A multi-hit therapeutic nanoplatform for hepatocellular carcinoma: Dual stimuli-responsive drug release, dual-modal imaging, and in situ oxygen supply to enhance synergistic therapy. Materials Today Bio, [PMID:35847375] [10.1016/j.mtbio.2022.100338] |
| 6. Jing Xu, Chang He, Yongsong Cai, Xipeng Wang, Jidong Yan, Jing Zhang, Fujun Zhang, Vilma Urbonaviciute, Yuanyuan Cheng, Shemin Lu, Rikard Holmdahl. (2024) NCF4 regulates antigen presentation of cysteine peptides by intracellular oxidative response and restricts activation of autoreactive and arthritogenic T cells. Redox Biology, [PMID:38547647] [10.1016/j.redox.2024.103132] |
